← Eichor
Condition: Polymorphic Post Transplant Lymphoproliferative Disorder Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Polymorphic Post Transplant Lymphoproliferative Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Phase 2 · 4 location(s) · Timothy Voorhees · NCT05786040Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Phase 1 · 2 location(s) · Timothy Voorhees · NCT06672705Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymp
Phase 2 · 1 location(s) · Reem Karmali · NCT06723457
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.